Indications
Lokelma is indicated for the treatment of hyperkalaemia in adult patients.
Composition
- Active substance
- sodium zirconium cyclosilicate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lokelma
- Active substance
- sodium zirconium cyclosilicate
- ATC code
- V03AE10
- Group
- Various
- Therapeutic area
- Hyperkalemia
- Marketing authorisation holder
- AstraZeneca AB
- Status
- Authorised
- EU authorisation
- 22 Mar 2018
- EMA product number
- EMEA/H/C/004029